Recent Finacing
Recent Raise
Facio Therapies develops small‑molecule DUX4 repressors for FSHD using patient‑derived cell screening and high‑throughput discovery in collaboration with Evotec to advance candidates toward preclinical lead selection.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor